Skip to main content
FT US Pharma and Biotech Summit 2020
Tuesday, 29 September 2020 12:00 AM ET

Past Event


29 - 30 Sep.

12:00 am ET | 1 day

FT US Pharma and Biotech Summit 2020

Resetting the Pharma Agenda for a Post-COVID-19 World

This industry-leading event brings together the world’s biggest pharma companies and other major organisations across the life sciences and health care value chain to discuss key trends and issues that will help prepare stakeholders for a new wave of disruption and innovation for thriving in a post-COVID world.

The life sciences sector is on the verge of a massive transformation —now more than ever due to the COVID-19 outbreak, especially placing the pharma and biotech companies under the scanner. From embracing a strategic approach to patient centricity to leveraging real-world evidence (RWE) for advancing potential therapies; and defining value and pricing of COVID-19 treatment to the changing role of genomics in mental health, the outlook for various verticals across the sector is making a shift. 

Register Now for free

However, pharma companies will look to drive growth through digital partnerships across the value chain and by expansion of research areas such as cell and gene therapies amidst the post- pandemic economic slowdown.

As the industry looks to invest in a “new normal”, it is imperative to bring a fresh perspective on the critical issues impacting the pharma and biotech companies such as the pharma pricing and politics, the potential of real-world evidence, and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.

FT US Pharma and Biotech Summit brings together leaders from across the industry to discuss these trends and create a successful life sciences ecosystem for a post-COVID world.    

Key issues to be addressed at the conference:

  • Pharma Pricing and Politics: How will COVID-19 reset the drug pricing debate?
  • Mission critical: Unlocking the potential of Real-World Evidence (RWE)  
  • Unconventional partnerships and collaborations in pharma
  • From patient centricity to true patient collaboration
  • New approaches for a new age of mental health
  • Future of cell and gene therapies

Deloitte participation sessions:

29 September 2020 | 10:05 a.m. – 10:55 a.m.


  • Tom Fezza, Partner Life Sciences and Health Care Strategy Advisor, Deloitte
  • Terry Wilcox, Co-Founder and Executive Director, Patients Rising


Hannah Kuchler, US Pharma and Biotech Correspondent, Financial Times

29 September 2020 | 11:35 a.m. – 12:25 p.m.


  • Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi
  • Everett Neville, Senior Vice President, Value Creation, Cigna 
  • Susan Shiff, Senior Vice President and Head of Center for Observational and Real-World Evidence (CORE), Merck
  • Joanne Waldstreicher, Chief Medical Officer, Johnson & Johnson


Neil Lesser, Principal, Research & Development Strategy Practice Lead, Deloitte

29 September 2020 | 12:20 p.m.


  • Margaret Anderson, Managing Director, Deloitte
  • William Lewis, Chairman and CEO, Insmed
  • Kimberly Haugstad, CEO, Global Genes


Sarah Neville, Global Pharmaceuticals Editor, Financial Times

29 September 2020 | 16:50 p.m. – 17:40 p.m. ET


  • Shabbir Dahod, CEO, TraceLink
  • Natalie Kofler, Founder, Editing Nature
  • David Lennon, President, AveXis
  • Hussain Mooraj, Principal, Deloitte

29 September 2020 | 14:35 p.m. – 15:25 p.m. ET


  • Rich Carter, Vice President, Chief Digital Officer, Eli Lilly and Company
  • Ofer Leidner, President and Co-Founder, Happify Health
  • Mary Rozenman, Chief Financial and Chief Business Officer, Insitro


Mike DeLone, Principal, US Life Sciences Sector Leader, Deloitte